Written by The Castleman disease treatment market is strategically focused on addressing the most challenging clinical scenarios where cytokine-driven systemic inflammation threatens multi-organ function and patient survival. Idiopathic multicentric Castleman disease (iMCD) represents the dominant clinical challenge, commanding 46.2% of market share in 2025, as this subtype presents with generalized lymphadenopathy, systemic inflammatory symptoms, and potentially fatal cytokine storm without targeted intervention. Siltuximab, the IL-6-directed monoclonal antibody approved by the FDA in 2014, achieved tumor and symptomatic response in 34% of patients in the pivotal Phase 2 trial, with durable responses lasting a median of 6.7 months and some patients maintaining benefit for years. Over 3,400 iMCD patients had received siltuximab globally by 2025, establishing it as the standard of care for first-line systemic therapy. However, approximately 50-60% of patients either fail to respond to IL-6 blockade or relapse after initial response, creating substantial unmet need for second-line and combination approaches.
HHV-8-associated multicentric Castleman disease captured 25.4% of market share, where rituximab monotherapy or combination with liposomal doxorubicin achieves high response rates by depleting HHV-8-infected B-cells that drive IL-6 and other cytokine production. Castleman Disease Treatment Market data indicates that rituximab achieves complete or partial response in 70-90% of HIV-positive HHV-8 MCD patients, with concurrent antiretroviral therapy essential for durable control. Over 2,800 HHV-8 MCD patients received rituximab-based treatment in 2025. The TAFRO clinical subtype is the fastest-growing therapeutic focus at 14.8% CAGR, as this severe presentation with thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly responds poorly to IL-6 blockade alone and requires intensified immunosuppression, rituximab, and sometimes cytotoxic chemotherapy.
Unicentric Castleman disease (UCD) represents a fundamentally different therapeutic paradigm, where complete surgical resection is curative in 85-90% of cases and adjuvant therapy is rarely required. However, unresectable UCD due to location or patient factors requires systemic therapy, with siltuximab, tocilizumab, and rituximab demonstrating activity. The expanding therapeutic landscape includes emerging approaches for refractory iMCD: sirolimus (mTOR inhibition), ruxolitinib (JAK1/2 inhibition), bortezomib (proteasome inhibition), and thalidomide analogs are being investigated in clinical trials and compassionate use settings. The Castleman Disease Collaborative Network’s treatment guidelines and international patient registry are generating real-world evidence that informs therapeutic sequencing and identifies predictors of response. As molecular profiling advances and patient stratification improves, Castleman disease treatment is transitioning from empiric cytokine blockade to precision medicine approaches that match therapeutic mechanisms to individual pathophysiology.
FAQs
Q1: What is the standard first-line treatment for iMCD? Siltuximab is the only FDA-approved iMCD treatment, achieving 34% response rate in pivotal trials with durable benefit, though 50-60% of patients fail initial or relapse after IL-6 blockade.
Q2: How effective is rituximab for HHV-8-associated MCD? Rituximab achieves 70-90% complete or partial response in HIV-positive HHV-8 MCD when combined with antiretroviral therapy, with over 2,800 patients treated in 2025.
Q3: What emerging therapies are being investigated for refractory Castleman disease? Emerging approaches include sirolimus (mTOR inhibition), ruxolitinib (JAK1/2 inhibition), bortezomib, thalidomide analogs, and combination regimens for TAFRO and refractory iMCD subtypes.